Improving Dissolution
Poor aqueous solubility is a recurring and increasing challenge for drug developers. With 40% of marketed drugs and up to 90% of those in development exhibiting poor solubility(1), finding solutions to overcome this challenge and increasing the bioavailability of compounds is as important now as it ever has been.
Crystec have experience in overcoming solubility challenges across a range of molecule classes (small and large molecules, natural products) and routes of administration (e.g. oral, inhaled, injectable). Crystec’s mSAS® (modified Supercritical Anti-Solvent) platform enables a range of strategies to be implemented, in isolation or in parallel, to improve rates of dissolution.
Novel solid state forms
Particle size and surface area
Manipulating particle shape
Scalable co-crystals
Active-enhancer composites
Stabilised amorphous particles
References: 1 Kalepua. S, Nekkantib. V, Acta Pharm Sin B. 2015 Sep; 5(5): 442–453
